Drug Trial Radar · NCT04674800
Extension Study of MYL-1701P-3001 for Safety and Efficacy
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Nov 23, 2020
Primary completion
Apr 20, 2022
Study completion Apr 20, 2022
Sponsor
- Lead sponsor
- Mylan Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- Collaborators
- Momenta Pharmaceuticals, Inc.
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
Conditions
- Diabetic Macular Edema
Interventions
MYL-1701P, a proposed biosimilar to EyleaBiological
MYL-1701P- 3 doses each of 2 mg at 8 weeks interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAEs).Time frame: Week 20
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Mylan Investigative site
Hyderabad, Andhra Pradesh, India
Mylan Investigative Site
Visakhapatnam, Andhra Pradesh, India
Mylan Investigative Site
Ahmedabad, Gujarat, India
Mylan Investigative site
Ahmedabad, Gujarat, India
Mylan Investigative site
Bangalore, Karnataka, India
Mylan Investigative Site
Bangalore, Karnataka, India
Mylan Investigative Site
Bengaluru, Karnataka, India
Mylan Investigative Site
Mumbai, Maharashtra, India
Mylan Investigative site
New Delhi, New Delhi, India
Mylan Investigative site
Bhubaneswar, Odisha, India
Mylan Investigative Site
Chandigarh, Punjab, India
Mylan Investigative site
Jaipur, Rajasthan, India
Mylan Investigative site
Madurai, Tamil Nadu, India
Mylan Investigative site
Tirunelveli, Tamil Nadu, India
Mylan Investigative Site
Noida, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.